Development of anti-OKT3 antibodies after OKT3 treatment.
The development of IgG and IgM anti-OKT3 antibodies the first 90 days after start of OKT3 treatment for acute cellular rejection was determined by ELISA in 25 consecutive renal transplant patients. The ELISA positive sera were then tested for neutralizing OKT3 antibodies by immunofluorescence inhibition assay utilizing the FACScan. The number of IgM positive patients was highest, four (16%) after 10 days of treatment and then declined. The highest number of patients, thirteen (56%) with IgG antibodies was found after 60 days. Sera with only IgM antibodies or with low IgG titers (< 1:100) did not neutralize OKT3. Five patients (20%) developed neutralizing antibodies. All of these patients had received OKT3 during an earlier transplantation. In four of these patients, the ACR had been reversed successfully before the development of antibodies, and in the last patient the ACR was reversed by a second course of Minnesota-ALG and increasing the dose of Cyclosporine. Monitoring the development of neutralizing anti-OKT3 antibodies is valuable in patients who have previously received OKT3 treatment.
Jensen
P B
PB
Department of Nephrology, Odense University Hospital, Denmark.
Birkeland
S A
SA
Rohrp
N
N
Elbirk
A
A
Jørgensen
K A
KA
D000906:Antibodies / Q000097:blood*; D000917:Antibody Formation; D005455:Fluorescent Antibody Technique; D006084:Graft Rejection / Q000628:therapy; D006801:Humans; D007074:Immunoglobulin G / Q000032:analysis; D007075:Immunoglobulin M / Q000032:analysis; D007166:Immunosuppressive Agents / Q000276:immunology* / Q000627:therapeutic use*; D016030:Kidney Transplantation; D016853:Muromonab-CD3 / Q000276:immunology* / Q000627:therapeutic use*
D000906:Antibodies; D007074:Immunoglobulin G; D007075:Immunoglobulin M; D007166:Immunosuppressive Agents; D016853:Muromonab-CD3